Leeward Investments LLC MA Grows Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA grew its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 405,506 shares of the life sciences company’s stock after acquiring an additional 29,402 shares during the quarter. Leeward Investments LLC MA owned about 0.53% of Integra LifeSciences worth $9,197,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in IART. KBC Group NV lifted its position in Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares in the last quarter. Empowered Funds LLC purchased a new position in Integra LifeSciences during the fourth quarter worth approximately $180,000. Centiva Capital LP purchased a new position in Integra LifeSciences during the third quarter worth approximately $192,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Integra LifeSciences during the third quarter worth approximately $198,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 3.10% of the company’s stock.

Integra LifeSciences Price Performance

IART stock opened at $21.13 on Friday. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.11. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The business has a fifty day moving average of $23.71 and a two-hundred day moving average of $21.81. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -234.75, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of analyst reports. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Citigroup raised their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and a consensus price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.